Drug Profile
JT 02 - JYANT Technologies
Alternative Names: JT02Latest Information Update: 19 Feb 2022
Price :
$50
*
At a glance
- Originator JYANT Technologies
- Class Antibodies
- Mechanism of Action Chemokine CXCL10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Inflammatory bowel diseases
Most Recent Events
- 19 Feb 2022 JT 02 is still in phase II trials for Inflammatory bowel diseases in USA (JYANT Technologies pipeline, February 2022)
- 11 Aug 2016 Phase-II clinical trials in Inflammatory bowel disease in USA (unspecified route)